Last quarter (Q4 2023), Nanobiotix's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Nanobiotix's net income was $―. See Nanobiotix’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ 36.21M	$ 4.78M	$ 2.65M	$ 2.51M	$ 68.00K
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 36.21M	$ 4.78M	$ 10.00K	$ 50.00K	$ ―
Operating Expense	$ ―	$ 62.99M	$ 64.36M	$ 49.81M	$ 36.30M	$ 46.85M
Operating Income	$ ―	$ -26.78M	$ -64.36M	$ -49.80M	$ -36.24M	$ -46.78M
Net Non Operating Interest Income Expense	$ ―	$ -6.48M	$ 3.53M	$ 6.36M	$ 201.00K	$ -4.55M
Other Income Expense	$ ―	$ 4.23M	$ -3.79M	$ 2.78M	$ -2.46M	$ 423.00K
Pretax Income	$ ―	$ -39.58M	$ -57.03M	$ -47.00M	$ -33.58M	$ -50.91M
Tax Provision	$ ―	$ 120.00K	$ 10.00K	$ 5.00K	$ 9.00K	$ 3.00K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -39.70M	$ -57.04M	$ -47.00M	$ -33.59M	$ -50.91M
Basic EPS	$ ―	$ -1.08	$ -1.64	$ -1.35	$ -1.38	$ ―
Diluted EPS	$ ―	$ -1.08	$ -1.64	$ -1.35	$ -1.38	$ ―
Basic Average Shares	$ ―	$ 36.93M	$ 34.85B	$ 34.73B	$ 24.39B	$ ―
Diluted Average Shares	$ ―	$ 36.93M	$ 34.78M	$ 34.82M	$ 24.34M	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ 9.44M
Total Expenses	$ ―	$ 62.99M	$ 64.36M	$ 49.81M	$ 36.30M	$ 46.85M
Net Income From Continuing And Discontinued Operation	$ ―	$ -39.70M	$ -57.04M	$ -47.00M	$ -33.59M	$ -50.91M
Normalized Income	$ ―	$ -29.09M	$ ―	$ ―	$ ―	$ -51.34M
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ 4.79M
EBIT	$ ―	$ -31.88M	$ -51.43M	$ -46.62M	$ -33.58M	$ -46.12M
EBITDA	$ ―	$ -30.37M	$ -49.93M	$ -45.06M	$ -31.83M	$ -44.35M

Currency in USD

Nanobiotix Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing